Benfotiamine

Jump to: navigation, search
Benfotiamine
Benfotiamine Wiki Str.png
Benfotiamine 3D.png
Clinical data
Trade namesMilgamma
SynonymsS-Benzoylthiamine O-monophosphate
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H23N4O6PS
Molar mass466.448 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Benfotiamine

Articles

Most recent articles on Benfotiamine

Most cited articles on Benfotiamine

Review articles on Benfotiamine

Articles on Benfotiamine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Benfotiamine

Images of Benfotiamine

Photos of Benfotiamine

Podcasts & MP3s on Benfotiamine

Videos on Benfotiamine

Evidence Based Medicine

Cochrane Collaboration on Benfotiamine

Bandolier on Benfotiamine

TRIP on Benfotiamine

Clinical Trials

Ongoing Trials on Benfotiamine at Clinical Trials.gov

Trial results on Benfotiamine

Clinical Trials on Benfotiamine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Benfotiamine

NICE Guidance on Benfotiamine

NHS PRODIGY Guidance

FDA on Benfotiamine

CDC on Benfotiamine

Books

Books on Benfotiamine

News

Benfotiamine in the news

Be alerted to news on Benfotiamine

News trends on Benfotiamine

Commentary

Blogs on Benfotiamine

Definitions

Definitions of Benfotiamine

Patient Resources / Community

Patient resources on Benfotiamine

Discussion groups on Benfotiamine

Patient Handouts on Benfotiamine

Directions to Hospitals Treating Benfotiamine

Risk calculators and risk factors for Benfotiamine

Healthcare Provider Resources

Symptoms of Benfotiamine

Causes & Risk Factors for Benfotiamine

Diagnostic studies for Benfotiamine

Treatment of Benfotiamine

Continuing Medical Education (CME)

CME Programs on Benfotiamine

International

Benfotiamine en Espanol

Benfotiamine en Francais

Business

Benfotiamine in the Marketplace

Patents on Benfotiamine

Experimental / Informatics

List of terms related to Benfotiamine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Benfotiamine (rINN, or S-benzoylthiamine O-monophosphate) is a synthetic S-acyl derivative of thiamine (vitamin B1).

It has been licensed for use in Germany since 1993 under the trade name Milgamma. (Combinations with pyridoxine or cyanocobalamin are also sold under this name.) It is prescribed there for treating sciatica and other painful nerve conditions.[1]

It is marketed as a medicine and/or dietary supplement, depending on the respective Regulatory Authority.[citation needed]

Uses

Benfotiamine is primarily marketed as an antioxidant dietary supplement. In a clinical study with six patients, benfotiamine lowered AGE by 40%.[2]

Benfotiamine may be useful for the treatment of diabetic retinopathy, neuropathy, and nephropathy however "Most of the effects attributed to benfotiamine are extrapolated from in vitro and animal studies. Unfortunately apparent evidences from human studies are scarce and especially endpoint studies are missing. Therefore additional clinical studies are mandatory to explore the therapeutic potential of benfotiamine in both diabetic and non-diabetic pathological conditions".[3] It is thought that treatment with benfotiamine leads to increased intracellular thiamine diphosphate levels,[3] a cofactor of transketolase. This enzyme directs advanced glycation and lipoxidation end products (AGE's, ALE's) substrates to the pentose phosphate pathway, thus reducing tissue AGEs.[4][5][6][7][8]

Pharmacology

After absorption, benfotiamine can be dephosphorylated by cells bearing an ecto-alkaline phosphatase to the lipid-soluble S-benzoylthiamine.[9] Benfotiamine should not be confused with allithiamine, a naturally occurring thiamine disulfide derivative with a distinct pharmacological profile.[10]

See also

References

  1. "BBC news story: Back pain drug 'may aid diabetics'". BBC News. 18 February 2003.
  2. J Lin, A Alt, J Liersch, RG Bretzel, M Brownlee (May 2000). "Benfotiamine Inhibits Intracellular Formation of Advanced Glycation End Products in vivo". Diabetes. 49 (Suppl1) (A143): 583.
  3. 3.0 3.1 Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A (2010). "The multifaceted therapeutic potential of benfotiamine". Pharmacol Res. 61 (6): 482–8. doi:10.1016/j.phrs.2010.02.008. PMID 20188835.
  4. Since AGEs are the actual agents productive of diabetic complications, in theory, if diabetic patients could block the action of AGEs completely by benfotiamine, strict blood sugar control, with its disruption of lifestyle and risks to health and life by severe hypoglycemic episodes, could be avoided, with revolutionary implications for the treatment of diabetes. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9(3):294-299
  5. Stirban A, Negrean M, Stratmann B; et al. (2007). "Adiponectin decreases postprandially following a heat-processed meal in individuals with type 2 diabetes: an effect prevented by benfotiamine and cooking method". Diabetes Care. 30 (10): 2514–6. doi:10.2337/dc07-0302. PMID 17630265.
  6. Stracke H, Hammes HP, Werkmann D; et al. (2001). "Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats". Exp. Clin. Endocrinol. Diabetes. 109 (6): 330–6. doi:10.1055/s-2001-17399. PMID 11571671.
  7. Stirban A, Negrean M, Stratmann B; et al. (2006). "Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes". Diabetes Care. 29 (9): 2064–71. doi:10.2337/dc06-0531. PMID 16936154.
  8. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003). "Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine". Diabetes. 52 (8): 2110–20. doi:10.2337/diabetes.52.8.2110. PMID 12882930.
  9. Yamazaki M (1968), Studies on the absorption of S-benzoylthiamine O-monophosphate : (I) Metabolism in tissue homogenates. Vitamins 38 (1) 12–20.
  10. M.L. Volvert, S. Seyen, M. Piette, B. Evrard, M. Gangolf, J.C. Plumier and L. Bettendorff (2008) Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacology 8: 10. http://dx.doi.org/10.1186/1471-2210-8-10

External links


Template:Vitamins Template:Neuropathic pain and fibromyalgia pharmacotherapies


Linked-in.jpg